Compare · MDLN vs TMCI
MDLN vs TMCI
Side-by-side comparison of Medline Inc. (MDLN) and Treace Medical Concepts Inc. (TMCI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and TMCI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 179.4x TMCI ($267.9M).
- MDLN has been more active in the news (7 items in the past 4 weeks vs 1 for TMCI).
- MDLN has more recent analyst coverage (25 ratings vs 19 for TMCI).
- Company
- Medline Inc.
- Treace Medical Concepts Inc.
- Price
- $35.95-1.74%
- $3.88-5.60%
- Market cap
- $48.08B
- $267.9M
- 1M return
- -
- -14.25%
- 1Y return
- -
- -39.66%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2021
- News (4w)
- 7
- 1
- Recent ratings
- 25
- 19
Treace Medical Concepts Inc.
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest TMCI
- Chief Legl & Comp Off, CorpSec Elder Scot Michael covered exercise/tax liability with 25,457 shares, decreasing direct ownership by 3% to 753,226 units (SEC Form 4)
- Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
- Chief Executive Officer Treace John T. bought $246,654 worth of shares (55,944 units at $4.41), increasing direct ownership by 0.76% to 7,404,383 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.
- Chief Innovation Officer Scanlan Sean F. covered exercise/tax liability with 9,814 shares, decreasing direct ownership by 1% to 679,863 units (SEC Form 4)
- Chief Financial Officer Hair Mark covered exercise/tax liability with 37,102 shares, decreasing direct ownership by 4% to 914,900 units (SEC Form 4)
- Chief Legl & Comp Off, CorpSec Elder Scot Michael covered exercise/tax liability with 16,253 shares, decreasing direct ownership by 2% to 778,683 units (SEC Form 4)
- SEC Form 10-Q filed by Treace Medical Concepts Inc.
- Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Treace Medical Concepts Reports Second Quarter 2026 Financial Results